Landmark Infrastructure Partners LP (LMRKO) Touches $24.65 Formed H&S; Atara Biotherapeutics (ATRA) Sellers Increased By 25.32% Their Shorts

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Logo

Landmark Infrastructure Partners LP (LMRKO) formed inverse H&S with $25.64 target or 4.00% above today’s $24.65 share price. Landmark Infrastructure Partners LP (LMRKO) has $358.69M valuation. The stock increased 0.61% or $0.15 during the last trading session, reaching $24.65. About 2,857 shares traded. Landmark Infrastructure Partners LP (NASDAQ:LMRKO) has declined 4.69% since June 30, 2017 and is downtrending. It has underperformed by 17.26% the S&P500.

Atara Biotherapeutics Inc (NASDAQ:ATRA) had an increase of 25.32% in short interest. ATRA’s SI was 5.42M shares in June as released by FINRA. Its up 25.32% from 4.33M shares previously. With 926,800 avg volume, 6 days are for Atara Biotherapeutics Inc (NASDAQ:ATRA)’s short sellers to cover ATRA’s short positions. The SI to Atara Biotherapeutics Inc’s float is 36.06%. The stock increased 1.66% or $0.6 during the last trading session, reaching $36.75. About 499,654 shares traded. Atara Biotherapeutics, Inc. (NASDAQ:ATRA) has risen 248.61% since June 30, 2017 and is uptrending. It has outperformed by 236.04% the S&P500. Some Historical ATRA News: 01/05/2018 – Atara Biotherapeutics Expands Comml Leadership Team With the Appointment of Manuela Maronati as General Manager, Europe; 08/05/2018 – Atara Biotherapeutics Expands T-Cell Immunotherapy Collaboration to Advance Next-Generation CAR T Technologies in Oncology, Aut; 08/05/2018 – ATARA CASH/INVESTMENTS AS OF MARCH 31 TOTALED $407.3M; 07/05/2018 – Genentech R&D leader Dietmar Berger moves to Atara Bio, heading up off-the-shelf T cell work; 08/05/2018 – ATARA BIOTHERAPEUTICS INC – CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS AS OF MARCH 31, 2018 TOTALED $407.3 MLN; 09/04/2018 – Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4); 07/05/2018 – #3 Genentech R&D leader Dietmar Berger moves to Atara Bio, heading up off-the-shelf T cell work @BrittanyMeiling; 29/05/2018 – Atara Biotherapeutics to Participate at Two Upcoming Investor Conferences; 07/05/2018 – Biotech Industry Veteran Dietmar Berger, M.D., Ph.D., Joins Atara Biotherapeutics as Global Head of Research and Development; 26/03/2018 – Atara Bio Presenting at Conference Tomorrow

Among 9 analysts covering Atara Biotherapeutics (NASDAQ:ATRA), 6 have Buy rating, 1 Sell and 2 Hold. Therefore 67% are positive. Atara Biotherapeutics had 11 analyst reports since January 3, 2018 according to SRatingsIntel. On Wednesday, February 28 the stock rating was downgraded by JMP Securities to “Market Perform”. The stock has “Buy” rating by Canaccord Genuity on Tuesday, January 30. Citigroup maintained it with “Sell” rating and $23 target in Monday, June 11 report. On Friday, April 6 the stock rating was maintained by William Blair with “Buy”. Citigroup downgraded the shares of ATRA in report on Thursday, February 15 to “Sell” rating. The stock of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) has “Buy” rating given on Tuesday, April 10 by J.P. Morgan. Jefferies maintained it with “Buy” rating and $46.0 target in Monday, March 5 report. On Wednesday, January 3 the stock rating was upgraded by Citigroup to “Neutral”.

Atara Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for patients with severe and life-threatening diseases in the United States. The company has market cap of $1.62 billion. The Company’s clinical stage T-cell product candidates include ATA129 that focuses on Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus associated post-transplant lymphoproliferative disorder after hematopoietic cell transplant and solid organ transplant; ATA188, which is in Phase I clinical trial for the treatment of multiple sclerosis; ATA520, a Phase I clinical trial product targeting cancers expressing the antigen Wilms tumor 1; and ATA230, which is Phase III clinical trials for refractory cytomegalovirus. It currently has negative earnings. The firm is also developing a next generation of allogeneic T-cell product candidates utilizing a technology to selectively enhance a T-cellÂ’s ability to target specific viral proteins implicated in disease.

Since January 10, 2018, it had 0 insider buys, and 31 sales for $20.10 million activity. Shares for $3.80M were sold by Clark Mitchall G.. The insider Ciechanover Isaac E. sold 48,500 shares worth $1.68M. Another trade for 12,286 shares valued at $535,301 was made by Fust Matthew K on Monday, May 14. 2,500 shares were sold by Gallagher Carol Giltner, worth $111,944 on Monday, June 18. Turner Heather D sold 12,214 shares worth $464,210. $735,357 worth of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) shares were sold by Porter Derrell. MCGRATH JOHN had sold 6,000 shares worth $242,460.

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Ratings Chart